TILT-123 is an oncolytic adenovirus encoding TNFα and IL-2. Here the authors report the results of a phase 1a trial of TILT-123 combined with anti-PD1 pembrolizumab in patients with platinum resistant or refractory ovarian cancer.
- Matthew Stephen Block
- James Hugo Armstrong Clubb
- Akseli Hemminki
